Global Cardiovascular Drugs Market 2012-2016

世界の心血管治療薬市場動向(2012-2016)

◆タイトル:Global Cardiovascular Drugs Market 2012-2016
◆商品コード:IRTNTR1958
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2013年3月22日
◆ページ数:100
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥336,000見積依頼/購入/質問フォーム
Five UserUSD3,300 ⇒換算¥369,600見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"世界の心血管治療薬市場動向(2012-2016)"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、主要地域別分析、主要国別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析等の情報をお届けいたします。

TechNavio’s analysts forecast the Global Cardiovascular Drugs market to decline at a CAGR of 10.47 percent over the period 2012-2016. One of the key factors affecting market growth is the over-dependency of the market on the US. The Global Cardiovascular Drugs market has also been witnessing an increase in R&D activities. However, the increase in healthcare expenditure could be one of the factors that will contribute to the growth of this market.

TechNavio’s report, the Global Cardiovascular Drugs Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Cardiovascular Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space are AstraZeneca plc, Bristol-Myers Squibb Co., Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi.

The other vendors mentioned in the report are Abbott Laboratories, Forest Laboratories Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Daiichi Sankyo Co. Ltd., GlaxoSmithKline plc, Solvay SA, Takeda Pharmaceutical Co. Ltd., and The Medicines Co.

Key questions answered in this report:
What will the market size be in 2016 and at what rate will it grow?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by these key vendors?
What are the strengths and weaknesses of these key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details provided within the report.

【資料の目次】

1. Executive Summary
2. Introduction
3. Market Coverage
Market Overview
Product Offerings
4. Market Landscape
4.1. Global Cardiovascular Drugs Market
Market Size and Forecast
4.2. Key Product Segmentation
4.3. Five Force Analysis
5. Global Anti-hypertensive Drugs Market
Market Overview
Market Size and Forecast
6. Best Selling Anti-hypertensive Drugs
6.1. Diovan/Co-Diovan
Market Overview
Market Size and Forecast
6.2. Blopress
Market Overview
Market Size and Forecast
6.3. Benicar/Benicar HCT
Market Overview
Market Size and Forecast
6.4. Micardis/Micardis HCT
Market Overview
Market Size and Forecast
6.5. Aprovel/CoAprovel (Avapro/Avalide)
Market Overview
Market Size and Forecast
6.6. Tekturna/Rasilez
Market Overview
Market Size and Forecast
6.7. Edarbi
Market Overview
6.8. Cozaar/Hyzaar
Market Overview
Market Size and Forecast
6.9. Norvasc
Market Overview
Market Size and Forecast
6.10. Exforge/Exforge HCT
Market Overview
Market Size and Forecast
6.11. Coversyl
Market Overview
Market Size and Forecast
6.12. Seloken/Toprol-XL
Market Overview
Market Size and Forecast
7. Global Anti-dyslipidemics Drugs Market
Market Overview
Market Size and Forecast
8. Best Selling Anti-dyslipidemic Drugs
8.1. Lipitor
Market Overview
Market Size and Forecast
8.2. Crestor
Market Overview
Market Size and Forecast
8.3. Niaspan
Market Overview
Market Size and Forecast
8.4. TriCor/Trilipix
Market Overview
Market Size and Forecast
8.5. Zetia/Vytorin
Market Overview
Market Size and Forecast
8.6. Tredaptive
Market Overview
9. Global Anti-thrombotics Drugs Market
Market Overview
Market Size and Forecast
10. Best Selling Anti-thrombotic Drugs
10.1. Plavix
Market Overview
Market Size and Forecast
10.2. Lovenox
Market Overview
Market Size and Forecast
10.3. Pradaxa
Market Overview
Market Size and Forecast
10.4. Xarelto
Market Overview
10.5. Brilique/Brilinta
Market Overview
10.6. Eliquis
Market Overview
11. Drug Pipeline Analysis
12. Geographical Segmentation
13. Key Leading Countries
USA
Germany
Japan
14. Rate of Incidence and Prevalence
Dyslipidemia
Hypertension
Hypercholesterolemia
Stroke
15. Vendor Landscape
16. Buying Criteria
17. Market Challenges
18. Market Growth Drivers
19. Drivers and their Impact
20. Impact of Drivers and Challenges
21. Market Trends
22. Key Vendor Analysis
22.1. Pfizer Inc.
22.1.1. Business Overview
22.1.2. Business Segmentation
22.1.3. Key Information
22.1.4. SWOT Analysis
22.2. Bristol-Myers Squibb Co.
22.2.1. Business Overview
22.2.2. Business Segmentation
22.2.3. Key Information
22.2.4. SWOT Analysis
22.3. AstraZeneca plc
22.3.1. Business Overview
22.3.2. Business Segmentation
22.3.3. Key Information
22.3.4. SWOT Analysis
22.4. Novartis AG
22.4.1. Business Overview
22.4.2. Business Segmentation
22.4.3. Key Information
22.4.4. SWOT Analysis
22.5. Merck & Co. Inc.
22.5.1. Business Overview
22.5.2. Business Segmentation
22.5.3. Key Information
22.5.4. SWOT Analysis
22.6. Sanofi S.A.
22.6.1. Business Overview
22.6.2. Business Segmentation
22.6.3. Key Information
22.6.4. SWOT Analysis
23. Other Reports in this Series
List of Exhibits:
Exhibit 1: Global Cardiovascular Drugs Market 2012-2016 (US$ billion)
Exhibit 2: Cardiovascular Drugs by Category Segmentation
Exhibit 3: Global Cardiovascular Drugs Market by Category Segmentation 2012 (percent)
Exhibit 4: Global Cardiovascular Drugs Market by Category Segmentation 2012-2016 (US$ million)
Exhibit 5: Global Cardiovascular Drugs Market by Category Segmentation 2012-2016 (in percent)
Exhibit 6: Global Anti-hypertensive Market 2012-2016 (US$ million)
Exhibit 7: Global Sales of Diovan/Co-Diovan 2012-2016 (US$ billion )
Exhibit 8: Global Sales of Blopress/Ecard (Atacand/Atacand Plus) 2012-2016 (US$ billion)
Exhibit 9: Global Sales of Benicar/Benicar HCT 2012-2016 (US$ billion)
Exhibit 10: Global Sales of Micardis/Micardis HCT 2012-2016 (US$ billion)
Exhibit 11: Global Sales of Aprovel/CoAprovel (Avapro/Avalide) 2012-2016 (US$ billion)
Exhibit 12: Global Sales of Tekturna/Rasilez 2012-2016 (US$ million)
Exhibit 13: Global Sales of Cozaar/Hyzaar 2012-2016 (US$ million)
Exhibit 14: Global Sales of Norvasc 2012-2016 (US$ billion)
Exhibit 15: Global Sales of Exforge/Exforge HCT 2012-2016 (US$ billion)
Exhibit 16: Global Sales of Coversyl 2012-2016 (US$ million)
Exhibit 17: Global Sales of Seloken/Toprol-XL 2012-2016 (US$ million)
Exhibit 18: Global Anti-dyslipidemic Market 2012-2016 (US$ million)
Exhibit 19: Global Sales of Lipitor 2012-2016 (US$ billion)
Exhibit 20: Global Sales of Crestor 2012-2016 (US$ billion)
Exhibit 21: Global Sales of Niaspan 2012-2016 (US$ million)
Exhibit 22: Global Sales of TriCor/Trilipix 2012-2016 (US$ million)
Exhibit 23: Global Sales of Zetia 2012-2016 (US$ billion)
Exhibit 24: Global Sales of Vytorin 2012-2016 (US$ billion)
Exhibit 25: Global Anti-thrombotic Market 2012-2016 (US$ million)
Exhibit 26: Global Sales of Plavix 2012-2016(US$ billion)
Exhibit 27: Global Sales of Lovenox 2012-2016 (US$ billion)
Exhibit 28: Global Sales of Pradaxa 2012-2016 (US$ million)
Exhibit 29: Oral HDL-C-raising Pipeline Drugs
Exhibit 30: Parenteral HDL-C-raising Pipeline Drugs
Exhibit 31: Severe Hypercholesterolemia Pipeline Drugs
Exhibit 32: Anti-inflammatory Pipeline Drugs
Exhibit 33: Heart Failure Pipeline Drugs
Exhibit 34: Global Cardiovascular Drugs Market by Geographical Segmentation 2012
Exhibit 35: Prevalence of Hypertension in 2012
Exhibit 36: Prevalence of Hypercholesterolemia in 2012
Exhibit 37: Prevalence of Stroke in 2012
Exhibit 38: Global Cardiovascular Drugs Market by Vendor Segmentation 2012
Exhibit 39: Global Cardiovascular Drugs Market by Vendor Segmentation 2016
Exhibit 40: Business Segmentation of Pfizer Inc.
Exhibit 41: Business Segmentation of Bristol-Myers Squibb Co.
Exhibit 42: Business Segmentation of AstraZeneca plc
Exhibit 43: Business Segmentation of Novartis AG
Exhibit 44: Business Segmentation of Merck & Co. Inc.
Exhibit 45: Business Segmentation of Sanofi S.A.



【掲載企業】

AstraZeneca plc, Bristol-Myers Squibb Co., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi.,Abbott Laboratories, Forest Laboratories Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Daiichi Sankyo Co. Ltd., GlaxoSmithKline plc, Solvay SA, Takeda Pharmaceutical Co. Ltd., The Medicines Co.

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[世界の心血管治療薬市場動向(2012-2016)] (Global Cardiovascular Drugs Market 2012-2016 / IRTNTR1958)販売に関する免責事項
[世界の心血管治療薬市場動向(2012-2016)] (Global Cardiovascular Drugs Market 2012-2016 / IRTNTR1958)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆